Related Experiment Videos
[Treatment of hematologic diseases with alpha interferon]
1Département d'hématologie clinique, Hôpital Saint-Louis, Paris, France.
Bulletin Du Cancer
|January 1, 1988
Summary
Natural alpha interferons, first studied in 1970, show promise for treating various cancers. Ongoing trials with recombinant alpha interferons continue to explore their efficacy in hematologic malignancies.
Area of Science:
- Hematology
- Oncology
- Immunotherapy
Context:
- Since 1970, clinical trials have investigated natural alpha interferons for treating specific disorders.
- Research has evolved to utilize recombinant alpha interferons for enhanced therapeutic applications.
Purpose:
- To review the historical use and ongoing research of alpha interferons in hematologic malignancies.
- To highlight the recognized sensitivity of certain disorders to interferon-based treatments.
Summary:
- Early trials identified disorders responsive to natural alpha interferons.
- Current research focuses on recombinant alpha interferons for treating hairy cell leukemia, low-grade lymphomas, myeloproliferative disorders, and myeloma.
Impact:
- Established alpha interferons as a viable treatment modality in specific hematologic cancers.
- Paved the way for recombinant interferon therapies in managing complex blood disorders.